slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
225,361-225,390 of 319,975
52
The waterfall plot shows sensitivity vs resistance. The right side shows a volcano plot for pathway analysis and a conceptual diagram for combination testing.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
53
The slide uses a combination of a bar chart for single-agent sensitivity and a heatmap for combination synergy results.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
54
The slide uses a Venn diagram to show gene overlap and line charts to show dose-response relationships for POLR2A and HNRNPDL.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
55
The slide features a 3D molecular visualization of the protein target.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
56
The slide uses a bar chart to demonstrate efficacy (reduction in PLN weight) at different doses of EXS4318 compared to a failed competitor drug.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
57
The slide uses a traffic-light color coding system to highlight the superior profile of EXS4318 compared to failed competitors.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
58
The slide uses a process-flow layout with icons and bulleted lists for each stage.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
59
The slide features a 3D molecular model, likely representing the target protein or the drug-target complex.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
60
The slide highlights the potential for '539 to address brain metastases in SCLC patients.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
61
The diagram illustrates the interaction network of LSD1 with various suppressors and activators.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
62
The slide uses a biological process diagram to explain the mechanism of action for an LSD1 inhibitor.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
63
The slide uses a process flow diagram to explain the therapeutic strategy.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
64
Exscientia | Investor Day Presentation Deck | 90 slidesExscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
65
The slide uses a three-column layout to define the strategic design requirements for a drug candidate.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
66
The slide uses a color-coded heatmap (green/yellow/red/grey) to indicate performance against criteria.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
67
The slide uses a horizontal process flow to map out the stages from initiation to synthesis.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
68
The slide uses a Pareto front to illustrate the trade-off between CNS score and Potency, highlighting that the 'best' molecules are not always the most information-rich.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
69
The slide uses two distinct chart types (dot plot and line chart) to demonstrate the safety profile of a reversible inhibitor compared to an irreversible one.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
70
The slide uses box plots for aggregate data and line charts for individual patient sample responses, categorized by differentiation potential.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
71
The chart compares single-agent activity (bar chart) against combination synergy (heatmap).Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
72
The slide includes two charts: a line chart showing tumour volume over time and a dot plot showing plasma pro-GRP concentration.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
73
The slide uses a heatmap to show synergy scores across different cell lines and treatments, and line charts to demonstrate dose-response curves for specific combinations.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
74
The heatmap displays AUC values for 16 patient samples across 3 treatments. Source: Okumura et al. ESMO, 2023.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
75
Exscientia | Investor Day Presentation Deck | 90 slidesExscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
76
MIDD = Model-informed Drug DevelopmentExscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
77
The slide features a stylized molecular visualization, likely representing the MALT1 protein target.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
78
Exscientia | Investor Day Presentation Deck | 90 slidesExscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
79
The slide uses a biological pathway diagram to illustrate the mechanism of action.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
80
Exscientia | Investor Day Presentation Deck | 90 slidesExscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit
81
Exscientia | Investor Day Presentation Deck | 90 slidesExscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action1 hit